title: Protective effects of haloperidol and clozapine on energy-deprived OLN-93 oligodendrocytes.
abstract: Magnetic resonance imaging and postmortem studies on schizophrenia provided evidence for compromised myelin integrity and reduced numbers of oligodendrocytes, which may worsen during the disease course. However, it is not clear whether these findings result from disease-inherent oligodendrocyte degeneration or side effects of antipsychotic treatment. Therefore, effects of haloperidol and clozapine on the viability and apoptosis of immature oligodendrocytes (OLN-93 cells, immunopositive for NG2, Olig1, Olig2) have been evaluated in the present study by labeling with propidium iodide and a caspase 3 assay. Given the indications for impaired cerebral energy supply in schizophrenia, a serum and glucose deprivation (SGD) model was chosen in comparison with the basal condition (BC). SGD led to increased necrotic and apoptotic cell death. Haloperidol and clozapine were partially protective in this model and reduced the percentage of propidium iodide-positive cells, while caspase 3 activity was not altered. No significant drug effects were observed under BC. The observed protective effects of haloperidol and clozapine on energy-deprived OLN-93 oligodendrocytes suggest that previously reported reductions in oligodendrocyte density in schizophrenia are rather disease related than a side effect of medication. A new mechanism of antipsychotic action is suggested, which may help to establish new oligodendrocyte-directed therapies of schizophrenia.
authors.affiliation: Department of Psychiatry, University of Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany. johann.steiner@med.ovgu.de
authors.forename: Johann
authors.initials: J
authors.lastname: Steiner
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Sarnyai
authors.forename: Sabine
authors.initials: S
authors.lastname: Westphal
authors.forename: Tomasz
authors.initials: T
authors.lastname: Gos
authors.forename: Hans-Gert
authors.initials: HG
authors.lastname: Bernstein
authors.forename: Bernhard
authors.initials: B
authors.lastname: Bogerts
authors.forename: Gerburg
authors.initials: G
authors.lastname: Keilhoff
mesh_terms: D000818:Animals; D000941:Antigens / Q000378:metabolism; D014150:Antipsychotic Agents / Q000494:pharmacology*; D051792:Basic Helix-Loop-Helix Proteins / Q000378:metabolism; D053148:Caspase 3 / Q000378:metabolism; D002461:Cell Line, Transformed; D003024:Clozapine / Q000494:pharmacology*; D016895:Culture Media, Serum-Free / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004734:Energy Metabolism / Q000187:drug effects*; D006220:Haloperidol / Q000494:pharmacology*; D009419:Nerve Tissue Proteins / Q000378:metabolism; D000076104:Oligodendrocyte Transcription Factor 2; D009836:Oligodendroglia / Q000187:drug effects*; D011509:Proteoglycans / Q000378:metabolism; D051381:Rats; D000099216:Chondroitin Sulfate Proteoglycan 4
chemical_list: D000941:Antigens; D014150:Antipsychotic Agents; D051792:Basic Helix-Loop-Helix Proteins; D053148:Caspase 3; D003024:Clozapine; D016895:Culture Media, Serum-Free; D006220:Haloperidol; D009419:Nerve Tissue Proteins; D000076104:Oligodendrocyte Transcription Factor 2; D011509:Proteoglycans; D000099216:Chondroitin Sulfate Proteoglycan 4; C498633:Olig1 protein, rat; C522729:Olig2 protein, rat